A UK government review in 2015, chaired by
economist Jim O'Neill, estimated that by 2050,
the global cost of antibiotic resistance will rise
to US$100 trillion and drug resistant infections
will cause 10 million deaths a year, eclipsing the
current toll from cancer and diabetes combined.
The government estimates there are currently
5,000 deaths each year in the UK because
antibiotics no longer work for some infections.
https://www.gov.uk/government/news/30-
million-of-funding-to-tackle-antimicrobial-
resistance
Neil Crabb, chief executive of Frontier IP, said:
"We are delighted to work with Amprologix
to commercialise these potentially life-saving
antibiotics, and with a leading industrial partner
in the area. It is further sign our business model
is gaining traction with universities and
industry alike."
Professor Mathew Upton, chief scientific officer
of Amprologix, said: "It is very exciting to form
a new company to take forwards our portfolio
of novel antimicrobial compounds. Epidermicin,
our lead candidate antibiotic, has excellent
potential for treating and preventing serious,
drug resistant infections. With our current team,
the company will be the ideal vehicle to take
epidermicin to the clinic."
Dr Ian Fotheringham, managing director of
Ingenza, said: "This unique partnership fully
exploits the synergy of Ingenza's versatile
bio-manufacturing technologies and
Amprologix's lead in discovering exciting
new antimicrobial classes, spearheaded by Dr
Upton's innovative research."
Article kindly provided by Frontier IP
Continued >>>
Professor Mathew Upton
